Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

NCT02281318 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

556

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

BIOLOGICAL: Mepolizumab
DRUG: Placebo
DRUG: SOC

Sponsor

GlaxoSmithKline